Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization.
PLoS One · 2014
Last updated 2026-05-28In a study on mice, the drug Exendin-4, given at doses of 5 or 50 micrograms per kilogram within 1.5 to 4.5 hours after a stroke, reduced brain injury in both young healthy mice and older mice with type 2 diabetes. The higher dose (50 µg/kg) was effective when given up to 3 hours after the stroke, while the lower dose (5 µg/kg) worked only within 1.5 hours. The drug also increased markers linked to M2 microglia, a type of cell involved in repair, suggesting it may help reduce stroke damage by promoting this repair process.
AI summary of the abstract below.
| Journal | PLoS One, 2014 |
|---|---|
| Citations | 82 |
| Relative citation ratio | 2.77 |
| NIH percentile | 82 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Alzheimers |
Abstract
Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has also shown neuroprotective effects in experimental stroke models. However, while the neuroprotective efficacy of Exendin-4 has been thoroughly investigated if the pharmacological treatment starts before stroke, the therapeutic potential of the Exendin-4 if the treatment starts acutely after stroke has not been clearly determined. Further, a comparison of the neuroprotective efficacy in normal and aged diabetic mice has not been performed. Finally, the cellular mechanisms behind the efficacy of Exendin-4 have been only partially studied. The main objective of this study was to determine the neuroprotective efficacy of Exendin-4 in normal and aged type 2 diabetic mice if the treatment started after stroke in a clinically relevant setting. Furthermore we characterized the Exendin-4 effects on stroke-induced neuroinflammation. Two-month-old healthy and 14-month-old type 2 diabetic/obese mice were subjected to middle cerebral artery occlusion. 5 or 50 µg/kg Exendin-4 was administered intraperitoneally at 1.5, 3 or 4.5 hours thereafter. The treatment was continued (0.2 µg/kg/day) for 1 week. The neuroprotective efficacy was assessed by stroke volume measurement and stereological counting of NeuN-positive neurons. Neuroinflammation was determined by gene expression analysis of M1/M2 microglia subtypes and pro-inflammatory cytokines. We show neuroprotective efficacy of 50 µg/kg Exendin-4 at 1.5 and 3 hours after stroke in both young healthy and aged diabetic/obese mice. The 5 µg/kg dose was neuroprotective at 1.5 hour only. Proinflammatory markers and M1 phenotype were not impacted by Exendin-4 treatment while M2 markers were significantly up regulated. Our results support the use of Exendin-4 to reduce stroke-damage in the prehospital/early hospitalization setting irrespectively of age/diabetes. The results indicate the polarization of microglia/macrophages towards the M2 reparative phenotype as a potential mechanism of neuroprotection.
Verbatim abstract via PubMed 25101679 ↗